Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

C. Arnold Spek

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2149-4068; OpenAlex author ID A5034585119. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 18)
Trials
0
Grants
0
Labs led
3
Collaborators
20
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 4 papers · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers · 2024: 3 papers

Papers 22

  1. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer. Last author DOI 10.1016/j.canlet.2024.216845↗
  2. Identification of pancreatic cancer-specific protease substrates for protease-dependent targeted delivery. Last author DOI 10.1038/s41389-024-00542-1↗
  3. Hypoxia Abrogates Tumor-Suppressive Activities of C/EBPδ in Pancreatic Cancer. Last author DOI 10.3390/ijms25179449↗
  4. C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC. Last author DOI 10.3390/ijms24021537↗
  5. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer. Last author DOI 10.3390/ijms241310704↗
  6. Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner. Co-author DOI 10.3390/biomedicines10020219↗
  7. C/EBPδ Suppresses Motility-Associated Gene Signatures and Reduces PDAC Cell Migration. Last author DOI 10.3390/cells11213334↗
  8. Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview. Last author DOI 10.3390/pharmaceutics14020390↗
  9. Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation. Last author DOI 10.3390/biom11081079↗
  10. ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer. Last author DOI 10.3390/cancers13133321↗
  11. Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation. Last author DOI 10.1007/s13402-020-00549-x↗
  12. Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion. Last author DOI 10.1186/s12885-020-07697-1↗
  13. Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression? Last author DOI 10.3390/biology9040080↗
  14. CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcino… Last author DOI 10.3390/cancers12092546↗
  15. PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. Last author DOI 10.18632/oncotarget.25880↗
  16. Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer. Co-author DOI 10.1016/j.thromres.2017.03.001↗
  17. Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice. Last author DOI 10.2119/molmed.2016.00214↗
  18. Authors' reply-Re: Shi et al. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer mod… First author DOI 10.1002/path.4499↗
  19. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. Last author DOI 10.1002/ijc.28726↗
  20. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. Last author DOI 10.1002/path.4411↗
  21. Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner. Last author DOI 10.1111/jth.12361↗
  22. mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. Co-author DOI 10.1200/jco.2010.32.7825↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maarten F. Bijlsma · 14 shared papers, 2018–2024 · strength 2.53
  2. JanWillem Duitman · 8 shared papers, 2014–2024 · strength 1.33
  3. Etienne J. Slapak · 6 shared papers, 2020–2024 · strength 1.27
  4. Leonie Hartl · 5 shared papers, 2020–2024 · strength 0.88
  5. Cansu Tekin · 4 shared papers, 2018–2020 · strength 0.52
  6. Frederike Dijk · 3 shared papers, 2020–2023 · strength 0.43
  7. Kun Shi · 6 shared papers, 2013–2018 · strength 0.43
  8. Dick J. Richel · 5 shared papers, 2011–2017 · strength 0.25
  9. Karla C. S. Queiroz · 4 shared papers, 2011–2014 · strength 0.17
  10. Mark P.G. Dings · 1 shared paper, 2020 · strength 0.09
  11. Maikel Petrus Peppelenbosch · 1 shared paper, 2020 · strength 0.09
  12. Marc G. Besselink · 1 shared paper, 2020 · strength 0.09
  13. I.T. Wilts · 1 shared paper, 2017 · strength 0.08
  14. Pieter Willem Kamphuisen · 1 shared paper, 2017 · strength 0.08
  15. Harry Roger Buller · 1 shared paper, 2017 · strength 0.08
  16. Helene Damhofer · 1 shared paper, 2017 · strength 0.08
  17. Johanna W. Wilmink · 1 shared paper, 2014 · strength 0.04
  18. Heinz‐Josef Klümpen · 1 shared paper, 2011 · strength 0.02
  19. G. Johan A. Offerhaus · 1 shared paper, 2011 · strength 0.02
  20. Roeland F. de Wilde · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.